Normal

3rd - 4th October 2019

5th Annual MarketsandMarkets Neuroscience R&D Technologies Conference

Radisson Blu Edwardian, Grafton Hotel, London

5+

Sessions

100+

Attendees

20

Speakers

10+

Networking Hours

Improving clinical translation in neuroscience research has always been a major challenge until now. There are many research collaborations happening in the neuroscience space today for neurodegenerative disorders research. The conference will focus on discussing the latest technologies in the preclinical, translational neuroscience space and also drawing the attention of the audience towards new innovations happening in translational neuroscience imaging. The conference further aims to bring in the experts from academia and industry together to discuss how to create new, more effective translational neuroscience drawing on novel technology and recent discoveries.

Learn from 20+ industry leading speakers who will be sharing their presentations on CNS drug discovery, Latest Optogenetic tools, kinematic techniques, Blood-Brain Barrier Proteomics and Non-Invasive electrical brain stimulation.

Case studies presented from leading technology collaborations, Interactive panel and breakout sessions along with Access to online presentations on-demand post-summit.

First ever conference on application of technology in developing neurological treatments.

Meet 100+ global heads of neuroscience from the industry and Academics.

WHAT TO EXPECT

CONFERENCE AGENDA

Day 1 Thu, 03-Oct-2019
Day 2 Fri, 04-Oct-2019

Registration

Welcome note from MarketsandMarkets Conferences

Opening Remarks from the Chairman

Keynote Presentation: Stimulating neurogenesis for treatment of neurodegenerative diseases

09:10 - 09:40 Georg Terstappen , Chief Scientific Officer, OxStem

Role of Human IPSCs in Neuroscience and Pain Research

Deciphering the Identity of DIPG Cells to Develop Targeted Therapy Utilizing Genetically Engineered hNSCs

09:40 - 10:10 Yang (Ted) Teng, Director, Laboratory of SCI, Stem Cell & Neurofacilitation Research, Harvard University

How can we achieve better translation from in vitro to the clinic in neuroscience?

10:10 - 10:25 Paul Karila, CSO, Cellectricon

Morning Refreshments and Poster Presentation | One-to-One Networking Meetings

A Human iPSC-based Technology Platform for Amyotrophic Lateral Sclerosis Neuroinflammation Drug Discovery

11:10 - 11:40 Steven Biesmans , Senior Scientist, UCB

AI-driven phenotypic drug discovery delivers first-in-class, clinically effective neuropsychiatric treatments

11:40 - 12:10 Emer Leahy , CEO , Psychogenics

Introduction to Axols capabilities and how they can support your research

12:10 - 12:40 Nicholas Clare, Head, Customer Solutions, Axol Bioscience

Cellular models of Parkinson’s disease using toxins involve different dopaminergic neuron death processes: impact on drug screening

12:40 - 13:10 Noelle Callizot, Co-Founder, CSO, Neuro-Sys

Lunch and Poster Presentation | One-to-One Networking Meetings

Human iPSC-derived cells: a powerful tool for neuropathic pain disease modelling

14:10 - 14:40 Silvia Cainarca, Principal Investigator, Project Leader, IMI2 project -NGN-PET, Italy

Degenerative synaptopathies – progress and challenges

14:40 - 15:10 Frank Hirth , Group Leader Neural Circuits and , Behaviour King’s College London, UK

Optimizing next-generation drug development: RNA medicine meets systems biology

15:10 - 15:40 Winston Hide , C0-Director Non-Coding RNA Core, Harvard University

Afternoon Refreshments and Poster Presentation | One-to-One Networking Meetings

Preclinical development of new therapeutics: Opportunities and challenges.

16:25 - 16:55 Arshad Majid , Professor of Cerebrovascular Neurology, Director, Comprehensive Cerebrovascular Research unit (CCRU), University of Sheffield

From Translational Science in an Academic Setting to Commercial R&D in a Corporate Setting: Crossing the ‘Valley of Death’

16:55 - 17:25 David Taggart , Chief Operating Officer, Glycyx Therapeutics, USA

Panel: Challenges in the translation of pre-clinical to clinical research in CNS drug discovery

Closing Remarks from the Chairman

Drinks Reception & Networking

Registration

Welcome note from MnM Conferences

Opening Remarks from the Chairman

09:10 - 09:15 Frank Hirth , Group Leader Neural Circuits and , Behaviour King’s College London, UK

Keynote Presentation: Cell-type specific profiling of human brain for novel therapeutic development

09:15 - 09:45 Xiao Xu, Co-Founder, Cerevance, UK

Biomarkers and CNS Models

Strategies to enhance memory in old age and dementia

09:45 - 10:15 Karl Peter Giese, Professor, Neurobiology of Mental Health, King’s College London

TMS electro-diagnostic markers as a clinical readout for testing novel CNS therapeutics

10:15 - 10:45 Isabella Premoli, Research Lead, The Science Behind

Morning Refreshments and Poster Presentation | One-to-One Networking Meetings

Why is Pharma so scared of psychiatric drug discovery is the fear justified?

11:35 - 12:05 Mark Tricklebank, Wellcome Trust Research Fellow, Neuroimaging, King’s College London, UK

A new functional in vitro assay for screening of antipsychotics

12:05 - 12:35 Olaf Schroder, CEO, Neuroproof, Germany

Neuromodulation and Deep Brain Stimulation

Neuroengineering solutions for brain repair

12:35 - 13:05 Michela Chiappalone , Team Leader, Italian Institute of Technology

Lunch and Poster Presentation | One-to-One Networking Meetings

Brain informatics – a gateway to cutting-edge brain research

14:05 - 14:35 Mufti Mahmud, Senior Lecturer, Computing & Technology, Nottingham Trent University,

Closing remarks from the Chairman

Afternoon Refreshments and End of Conference

CONFERENCE SPEAKERS

Advisors

Georg Terstappen

Georg Terstappen
Chief Scientific Officer, OxStem

Frank Hirth

Frank Hirth
Group Leader Neural Circuits and , Behaviour King’s College London, UK

Speakers

Shailendra Singh (Shelly)

Shailendra Singh (Shelly)
Board Member, MarketsandMarkets

Georg Terstappen

Georg Terstappen
Chief Scientific Officer, OxStem

Arshad Majid

Arshad Majid
Professor of Cerebrovascular Neurology, Director, Comprehensive Cerebrovascular Research unit (CCRU), University of Sheffield

Frank Hirth

Frank Hirth
Group Leader Neural Circuits and , Behaviour King’s College London, UK

Emer Leahy

Emer Leahy
CEO , Psychogenics

Winston Hide

Winston Hide
C0-Director Non-Coding RNA Core, Harvard University

Yang (Ted) Teng

Yang (Ted) Teng
Director, Laboratory of SCI, Stem Cell & Neurofacilitation Research, Harvard University

Mark Tricklebank

Mark Tricklebank
Wellcome Trust Research Fellow, Neuroimaging, King’s College London, UK

SPONSORS

Gold

example-image — Axol Bioscience

Sponsors & Exhibitors

example-image — PsychoGenics

example-image — Cellectricon

example-image — QPS

NeuroProof

example-image — Neuro-Sys

example-image — Biorasi

example-image — Transpharmation

Clinical Neuroscience Partner

example-image — The Science Behind

PARTNERS

Supporting Association

BioPartner UK

EuropaBio

Neuromodec

Media Partners

example-image — GEN

example-image — SciDoc Publishers

example-image — Technology Networks

example-image — MedNous

example-image — PharmaTutor

example-image — PharmaVOICE

LOCATION

Radisson Blu Edwardian, Grafton Hotel, London

About the Hotel

5th Annual Neuroscience R&D Technologies Conference
will be held in London, UK

For any queries regarding the hotel booking please write to us at [email protected]

Hotel Booking Link

You will receive a link to book your accommodation via email once you are fully registered. (Please note that we do not authorize any 3rd party agencies (e.g. Exhibitors Housing Management) to book on our behalf and, occasionally, companies fraudulently try to represent us. If you are contacted by anyone other than us regarding your accommodation requirements for this event, please let us know immediately on [email protected]

PAST EVENT GALLERY